Insider · CIK 0002048409

Gallagher Kathleen P.

Reports to the SEC for 2 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0002048409

Forms 4 and 5

Insider transactions

42 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-18	RNAAtrium Therapeutics, Inc.F Tax Payment	Director, See Remarks	FTax Payment	−11.6K sh	$8.95	−$104K	119,729
2026-04-20	RNAAtrium Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, See Remarks	AAward	+205K sh	—	—	205,000
2026-04-20	RNAAtrium Therapeutics, Inc.A Award	Director, See Remarks	AAward	+103K sh	—	—	131,361
2026-02-27	RNAMAvidity Biosciences, Inc.D Disposition to Issuer	Chief Program Officer	DDisposition to Issuer	−80.3K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Program Officer	DDisposition to Issuer	−27.6K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Program Officer	DDisposition to Issuer	−13.4K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Program Officer	DDisposition to Issuer	−9,244 sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Program Officer	DDisposition to Issuer	−13.8K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Program Officer	DDisposition to Issuer	−22.3K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Program Officer	DDisposition to Issuer	−50K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Program Officer	DDisposition to Issuer	−16K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Program Officer	DDisposition to Issuer	−13.5K sh	—	—	0
2026-02-27	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Program Officer	DDisposition to Issuer	−42.5K sh	—	—	0
2025-12-17	RNAMAvidity Biosciences, Inc.A Award	Chief Program Officer	AAward	+72K sh	—	—	122,204
2025-12-17	RNAMAvidity Biosciences, Inc.F Tax Payment	Chief Program Officer	FTax Payment	−33.3K sh	$71.87	−$2.4M	88,868
2025-12-17	RNAMAvidity Biosciences, Inc.F Tax Payment	Chief Program Officer	FTax Payment	−8,030 sh	$71.87	−$577K	80,838
2025-09-02	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−188 sh	$47.42	−$8,914.96	50,204
2025-06-17	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−911 sh	$30.24	−$27.5K	50,392
2025-06-02	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	+5,875 sh	$16.65	+$97.8K	56,429
2025-06-02	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−5,875 sh	$32.48	−$191K	50,554
2025-06-02	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	−5,875 sh	—	—	22,596
2025-05-01	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	−5,875 sh	—	—	28,471
2025-05-01	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−5,875 sh	$32.40	−$190K	50,554
2025-05-01	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	+5,875 sh	$16.65	+$97.8K	56,429
2025-04-01	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	−329 sh	—	—	34,346
2025-04-01	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	−5,546 sh	—	—	13,829
2025-04-01	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	+329 sh	$16.65	+$5,477.85	50,883
2025-04-01	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−5,546 sh	$27.83	−$154K	50,554
2025-04-01	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	+5,546 sh	$14.70	+$81.5K	56,100
2025-04-01	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−329 sh	$27.83	−$9,155.215	50,554
2025-03-03	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−5,875 sh	$29.41	−$173K	50,554
2025-03-03	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	+5,875 sh	$14.70	+$86.4K	56,429
2025-03-03	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	−5,875 sh	—	—	19,375
2025-02-03	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−5,875 sh	$32.16	−$189K	50,554
2025-02-03	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	−5,875 sh	—	—	34,675
2025-02-03	RNAMAvidity Biosciences, Inc.M Exercise/Conversion	Chief Program Officer	MExercise/Conversion	+5,875 sh	$16.65	+$97.8K	56,429
2025-01-22	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−5,629 sh	$30.16	−$170K	50,554
2025-01-21	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−1,817 sh	$28.59	−$52K	56,183
2025-01-21	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−670 sh	$28.60	−$19.2K	58,000
2025-01-21	RNAMAvidity Biosciences, Inc.S Sale	Chief Program Officer	SSale	−1,295 sh	$28.59	−$37K	58,670
2025-01-06	RNAMAvidity Biosciences, Inc. · Stock Option (Right to Buy)A Award	Chief Program Officer	AAward	+50K sh	—	—	50,000
2025-01-06	RNAMAvidity Biosciences, Inc.A Award	Chief Program Officer	AAward	+25K sh	—	—	59,965

Recent filings

Accepted (ET)
Sep 224
Gallagher Kathleen P.0001193125-26-397944
SEC(opens sec.gov)
Apr 224
Gallagher Kathleen P.0001193125-26-170914
SEC(opens sec.gov)
Feb 274
Gallagher Kathleen P.0001193125-26-082228
SEC(opens sec.gov)
Dec 194
Gallagher Kathleen P.0001599901-25-000215
SEC(opens sec.gov)
Sep 24
Gallagher Kathleen P.0001599901-25-000171
SEC(opens sec.gov)
Jun 184
Gallagher Kathleen P.0001599901-25-000131
SEC(opens sec.gov)
Jun 44
Gallagher Kathleen P.0001599901-25-000109
SEC(opens sec.gov)

Companies

Address

C/O ATRIUM THERAPEUTICS, INC. 10578 SCIENCE CENTER DRIVE, SUITE 125

SAN DIEGO, CA, 92121